Current developments in nucleoside/nucleotide analogues for hepatitis B

References

• Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30:2212-19
   PubMed Web of Science ®Google Scholar
• Chan HL, Jia JD. Chronic Hepatitis B in Asia – new insights from the past decade. J Gastroenterol Hepatol 2011;26(Suppl 1):131-7
   PubMedGoogle Scholar
• Dan YY, Aung MO, Lim SG. The economics of treating chronic hepatitis B in Asia. Hepatol Int 2008;2:284-95
   PubMed Web of Science ®Google Scholar
• Jonas MM. Hepatitis B and pregnancy: an underestimated issue. Liver Int 2009;29(Suppl 1):133-9
   PubMedGoogle Scholar
• Davis LG, Weber DJ, Lemon SM. Horizontal transmission of hepatitis B virus. Lancet 1989;1(8643):889-93
   PubMed Web of Science ®Google Scholar
• World Health Organization. Immunization, vaccines and biologicals. Available from: www.who.int/immunization/topics/hepatitis_b/en/index.html
   Google Scholar
• Sung JJ, Tsoi KK, Wong VW, et al. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008;28:1067-77
   PubMed Web of Science ®Google Scholar
• Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. The Control of Chronic Hepatitis B: The role of chemoprevention. Semin Liver Dis 2006;26:153-61
   PubMed Web of Science ®Google Scholar
• Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73
   PubMed Web of Science ®Google Scholar
• Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-86
   PubMed Web of Science ®Google Scholar
• Chan HL, Tse CH, Mo F, et al. High viral load and hepatitis B virus subgenotype Ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 2008;26:177-82
   PubMed Web of Science ®Google Scholar
• Wong VW, Chan SL, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010;28:1660-5
   PubMed Web of Science ®Google Scholar
• Yuen MF, Tanaka Y, Fong DY, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009;50:80-8
   PubMed Web of Science ®Google Scholar
• Yang HI, Yuen MF, Chan HL, et al. Development and validation of a predictive score describing risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): prospective analysis. Lancet Oncol 2011;12:568-74
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2009;50:661-2
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2012;57:167-85
   PubMed Web of Science ®Google Scholar
• Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: 1 2012 update. Hepatol Int 2012;6:531-61
   PubMed Web of Science ®Google Scholar
• Castera L, Pinzani M, Bosch J. Non-invasive evaluation of portal hypertension using transient elastography. J Hepatol 2012;56:696-703
   PubMed Web of Science ®Google Scholar
• Wong GL. Transient elastography: kill two birds with one stone? World J Hepatol 2013;5:264-74
   PubMedGoogle Scholar
• Chan HL, Wong GL, Choi PC, et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat 2009;16:36-44
   PubMed Web of Science ®Google Scholar
• Wong GL, Wong VW, Choi PC, et al. Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients. Clin Gastroenterol Hepatol 2009;7:227-33
   PubMed Web of Science ®Google Scholar
• Tong MJ, Hsien C, Hsu L, et al. Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Hepatology 2008;48:1070-8
   PubMed Web of Science ®Google Scholar
• Wong DK, Cheung AM, O’Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-23
   PubMed Web of Science ®Google Scholar
• Vial T, Descotes J. Clinical toxicity of the interferons. Drug Saf 1994;10:115-50
   PubMed Web of Science ®Google Scholar
• Wong VW, Wong GL, Yan KK, et al. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen positive chronic hepatitis B. Hepatology 2010;51:1945-53
   PubMed Web of Science ®Google Scholar
• Wong GL, Chan HL. Predictors of treatment response in chronic hepatitis B. Drug 2009;69:2167-77
   PubMed Web of Science ®Google Scholar
• Lai CL, Chien RN, Leung WY, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia hepatitis lamivudine study group. N Engl J Med 1998;339:61-8
   PubMed Web of Science ®Google Scholar
• Seok JI, Lee DK, Lee CH, et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology 2009;49:2080-6
   PubMed Web of Science ®Google Scholar
• Kim BK, Oh J, Kwon SY, et al. Clevudine myopathy in patients with chronic hepatitis B. J Hepatol 2009;51:829-34
   PubMed Web of Science ®Google Scholar
• Chan HL. Antiviral therapy for chronic hepatitis B: the challenges of Hong Kong. J Hepatol 2009;51:1088-90
   PubMed Web of Science ®Google Scholar
• Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007. 5:890-7
   Google Scholar
• Nassal M. Hepatitis B viruses: reverse transcription a different way. Virus Res 2008;134:235-49
   PubMed Web of Science ®Google Scholar
• Urban S, Schulze A, Dandri M, et al. The replication cycle of hepatitis B virus. J Hepatol 2010;52:282-4
   PubMed Web of Science ®Google Scholar
• Chan HL, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 – a core group report. J Hepatol 2011;55:1121-31
   PubMed Web of Science ®Google Scholar
• Chan HL, Wang H, Niu J, et al. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther 2007;12:345-53
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sevastianos V, Rapti IN, et al. Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg-negative chronic hepatitis B. Hepatology 2006;44(Suppl1):231A
   Google Scholar
• Jeng WJ, Sheen IS, Chen YC, et al. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology 2013;58:1888-96
   PubMed Web of Science ®Google Scholar
• Reijnders JG, Perquin MJ, Zhang N, et al. Nucleos(t)ide analogs only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010;139(2):491-8
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003;37:748-55
   PubMed Web of Science ®Google Scholar
• Poynard T, Hou J, Chutaputti A, et al. Sustained durability of HBeAg seroconversion in chronic hepatitis B patients after treatment with telbivudine and lamivudine. J Hepatol 2008;48:S263
   Web of Science ®Google Scholar
• Jaroszewicz J, Calle Serrano B, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010;52:514-22
   PubMed Web of Science ®Google Scholar
• Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007;5:1462-8
   PubMed Web of Science ®Google Scholar
• Chan HL, Wong VW, Wong GL, et al. A longitudinal study on the natural history of serum HBsAg changes in chronic hepatitis B. Hepatology 2010;52:1232-41
   PubMed Web of Science ®Google Scholar
• Jaroszewicz J, Ho H, Deterding K, et al. Prediction of HBsAg loss by quantitative HBsAg kinetics during long-term treatment with nucleos(t)ide analogues. Hepatology 2010;52:Abstract 395
   Web of Science ®Google Scholar
• Reijnders JG, Rijckborst V, Sonneveld MJ, et al. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 2011;54:449-54
   PubMed Web of Science ®Google Scholar
• Seto WK, Liu K, Wong DK, et al. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. J Hepatol 2013;59(4):709-16
   PubMed Web of Science ®Google Scholar
• Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis virus genotype D carriers. Gastroenterology 2010;139:483-90
   PubMed Web of Science ®Google Scholar
• Chan HL, Wong GL, Tse CH, et al. Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. J Infect Dis 2011;204:408-14
   PubMed Web of Science ®Google Scholar
• Seto WK, Wong DK, Fung J, et al. A large case-control study on the predictability of hepatitis B surface antigen (HBsAg) levels three years before HBsAg seroclearance. Hepatology 2012;56:812-19
   PubMed Web of Science ®Google Scholar
• Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-95
   PubMed Web of Science ®Google Scholar
• Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-9
   PubMed Web of Science ®Google Scholar
• Chan HL, Hui AY, Wong VW, et al. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology 2005;41:1357-64
   PubMed Web of Science ®Google Scholar
• Wong GL, Chan HL. Predictors of treatment response in chronic hepatitis B. Drugs 2009;69:2167-77
   PubMed Web of Science ®Google Scholar
• Westland C, Delaney W, Yang H, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology 2003;125:107-16
   PubMed Web of Science ®Google Scholar
• Chan HL, Wong ML, Hui AY, et al. Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment. World J Gastroenterol 2003;9:2695-7
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63
   PubMed Web of Science ®Google Scholar
• Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31
   PubMed Web of Science ®Google Scholar
• Chan HL, Wong VW, Hui AY, et al. Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B. Antivir Ther 2006;11(4):465-71
   PubMed Web of Science ®Google Scholar
• Wong VW, Wong GL, Tsang SW, et al. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. Antivir Ther 2008;13(4):571-9
   PubMed Web of Science ®Google Scholar
• Lok AS, Lai CL, Leung WY, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-22
   PubMed Web of Science ®Google Scholar
• Allen MI, DesLauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998;27:1670-7
   PubMed Web of Science ®Google Scholar
• Libbrecht E, Doutreloigne J, Van De Velde H, et al. Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay. J Clin Microbiol 2007;45(12):3935-41
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16
   PubMed Web of Science ®Google Scholar
• Hadziayannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7
   PubMed Web of Science ®Google Scholar
• Hadziayannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-51
   PubMed Web of Science ®Google Scholar
• Hartono JL, Aung MO, Dan YY, et al. Resolution of adefovir-related nephrotoxicity by adefovir dose-reduction in patients with chronic hepatitis B. Aliment Pharmacol Ther 2013;37:710-19
   PubMed Web of Science ®Google Scholar
• Kim du H, Sung DH, Min YK. Hypophosphatemic osteomalacia induced by low-dose adefovir therapy: focus on manifestations in the skeletal system and literature review. J Bone miner Metab 2013;31(2):240-6
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011;364:322-31
   PubMed Web of Science ®Google Scholar
• Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10
   PubMed Web of Science ®Google Scholar
• Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20
   PubMed Web of Science ®Google Scholar
• Leung N, Peng CY, Hann HW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009;49:72-9
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009;49:1503-14
   PubMed Web of Science ®Google Scholar
• Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance mechanisms, detection and interpretation. J Hepatol 2006;44:593-606
   PubMed Web of Science ®Google Scholar
• Reijnders JG, Deterding K, Petersen J, et al. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol 2010;52:493-500
   PubMed Web of Science ®Google Scholar
• Ong A, Wong VW, Wong GL, et al. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. Aliment Pharmacol Ther 2011;34:972-81
   PubMed Web of Science ®Google Scholar
• Lange CM, Bojunga J, Hofmann WF, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009;50:2001-6
   PubMed Web of Science ®Google Scholar
• Wong VW, Wong GL, Yiu KK, et al. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol 2011;54:236-42
   PubMed Web of Science ®Google Scholar
• Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62-72
   PubMed Web of Science ®Google Scholar
• Wong GL, Chan HL, Chan HY, et al. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology 2013;144:933-44
   PubMed Web of Science ®Google Scholar
• Wong GL, Chan HL, Mak CH, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Wong GL. Who will have the best response to entecavir? J Gastroenterol Hepatol 2013;28:5-7
   PubMed Web of Science ®Google Scholar
• Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886-93
   PubMed Web of Science ®Google Scholar
• Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-88
   PubMed Web of Science ®Google Scholar
• Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir. Ann Intern Med 2007;147:745-54
   PubMed Web of Science ®Google Scholar
• Chan HL, Chen YC, Gane EJ, et al. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis. J Viral Hepat 2012;19:732-43
   PubMed Web of Science ®Google Scholar
• Gane EJ, Deray G, Liaw YF, et al. Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology 2014;146(1):138-146.e5
   PubMed Web of Science ®Google Scholar
• Liaw YF, Gane E, Leung N, et al. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486-95
   PubMed Web of Science ®Google Scholar
• Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil Fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-55
   PubMed Web of Science ®Google Scholar
• Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140:132-43
   PubMed Web of Science ®Google Scholar
• Tan J, Degertekin B, Wong SN, et al. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 2008;48:391-8
   PubMed Web of Science ®Google Scholar
• van Bömmel F, Trojan J, Deterding K, et al. Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy. Antivir Ther 2012;17(6):1049-58
   PubMed Web of Science ®Google Scholar
• Sheldon J, Camino N, Rodes B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005;10:727-34
   PubMed Web of Science ®Google Scholar
• Amini-Bavil-Olyaee S, Herbers U, Sheldon J, et al. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology 2009;49:1158-65
   PubMed Web of Science ®Google Scholar
• Cooper RF, Wiebe N, Smith N, et al. Systemic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010;51:496-505
   PubMed Web of Science ®Google Scholar
• van Bömmel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010;51:73-80
   PubMed Web of Science ®Google Scholar
• Gish RG, Clark MD, Kane SD, et al. Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. Clin Gastroenterol Hepatol 2012;10(8):941-6
   PubMed Web of Science ®Google Scholar
• Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468-75
   PubMed Web of Science ®Google Scholar
• Yoo BC, Kim JH, Chung YH, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007;45:1172-8
   PubMed Web of Science ®Google Scholar
• Yoo BC, Kim JH, Kim TH, et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 2007;46:1041-8
   PubMed Web of Science ®Google Scholar
• Yuen MF, Seto WK, Chow DH, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007;12:1295-303
   PubMed Web of Science ®Google Scholar
• Eun JR, Lee HJ, Lee SH, et al. The effect of lamivudine and adefovir dipivoxil on preventing hepatocellular carcinoma in hepatitis B virus-related liver cirrhosis. Hepatology 2007;46:664A-5A
   Web of Science ®Google Scholar
• Wong VW, Chan HL. Severe acute exacerbation of chronic hepatitis B: a unique presentation of a common disease. J Gastroenterol Hepatol 2009;24:1179-86
   PubMedGoogle Scholar
• Chan HL, Wong VW, Hui AY, et al. Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B. Antivir Ther 2006;11:465-71
   PubMed Web of Science ®Google Scholar
• Wong VW, Wong GL, Yiu KK, et al. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol 2011;54:236-42
   PubMed Web of Science ®Google Scholar
• Shiffman ML. Management of acute hepatitis B. Clin Liver Dis 2010;14:75-91
   PubMed Web of Science ®Google Scholar
• Loomba R, Rowley AK, Wesley R, et al. Hepatitis B immunoglobulin and lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol 2008;6:696-700
   PubMed Web of Science ®Google Scholar
• Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011;141:1212-19
   PubMed Web of Science ®Google Scholar
• Fung J, Chan SC, Cheung C, et al. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. Am J Gastroenterol 2013;108:942-8
   PubMed Web of Science ®Google Scholar
• Shouval D, Shibolet O. Immunosuppression and HBV reactivation. Semin Liver Dis 2013;33:167-77
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan HL. Hepatitis B virus reactivation associated with anti-neoplastic therapy. J Gastroenterol Hepatol 2013;28(1):31-7
   PubMed Web of Science ®Google Scholar
• Gavazzi G, Bouchard O, Leclercq P, et al. Change in transaminases in hepatitis C virus- and HIV co-infected patients after highly active antiretroviral therapy: differences between complete and partial virologic responders? AIDS Res Hum Retroviruses 2000;16:1021-3
   PubMed Web of Science ®Google Scholar
• Drake A, Mijch A, Sasadeusz J. Immune reconstitution hepatitis in HIV and hepatitis B co-infection despite lamivudine therapy as a part of HAART. Clin Infect Dis 2004;39:129-32
   PubMed Web of Science ®Google Scholar
• Shi Z, Yang Y, Ma L, et al. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus, A systematic review and meta-analysis. Obstet Gynecol 2010;116:147-59
   PubMed Web of Science ®Google Scholar
• Sung JJ, Lai JY, Zeuzem S, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008;48:728-35
   PubMed Web of Science ®Google Scholar
• Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528-36
   PubMed Web of Science ®Google Scholar
• Lok AS, Trinh H, Carosi G, et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Gastroenterology 2012;143:619-28
   PubMed Web of Science ®Google Scholar
• Petersen J, Ratziu V, Buti M, et al. Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study. J Hepatol 2012;56:520-6
   PubMed Web of Science ®Google Scholar
• Si-Ahmed SN, Pradat P, Zoutendijk R, et al. Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study. Antiviral Res 2011;92:90-5
   PubMed Web of Science ®Google Scholar
• Chan HL, Hui AJ, Chan S, et al. Tenofovir DF (TDF) compared to emtricitabine (FTC)/TDF in HBeAg-positive, chronic hepatitis B (CHB) virus-infected patients in the immune tolerant (IT) phase. 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013) ( Abstract 101 24-28 April 2013, Amsterdam, Netherlands
   Google Scholar
• Chen X, Cao Z, Liu Y, et al. Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog. J Gasteoenterol Hepatol 2012;27(3):481-6
   PubMed Web of Science ®Google Scholar
• Piratvisuth T, Lau GK, Chao YC, et al. Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int 2008;2:102-10
   PubMed Web of Science ®Google Scholar
• Piccolo P, Lenci I, Demelia L, et al. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen negative chronic hepatitis B. Antivir Ther 2009;14:1165-74
   PubMed Web of Science ®Google Scholar
• Sarin SK, Sood A, Kumar M, et al. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 2007;102(1):96-104
   PubMed Web of Science ®Google Scholar
• Moucari R, Boyer N, Ripault MP, et al. Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients. J Viral Hepat 2011;18:580-6
   PubMed Web of Science ®Google Scholar
• Chen CC, Wang PC, Chang HW, Chen CF. Safety and efficacy of two-step peginterferon a-2a treatment in patients of chronic hepatitis B with acute exacerbation. J Viral Hepat 2012;19:161-92
   PubMed Web of Science ®Google Scholar
• Safadi R, Xie Q, Chen Y, et al. Efficacy of switching to telbivudine in chronic hepatitis B patients treated previously with lamivudine. Liver Int 2011;31(5):667-75
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009;51:11-20
   PubMed Web of Science ®Google Scholar
• Seto WK, Lai CL, Fung J, et al. Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. J Hepatol 2011;55:522-8
   PubMed Web of Science ®Google Scholar
• Piratvisuth T, Komolmit P, Tanwandee T, et al. 52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. PLoS One 2013;8(2):e54279
   PubMed Web of Science ®Google Scholar
• Yu HC, Lin KH, Hsu PI, et al. Real-would application of the roadmap model in chronic hepatitis B patients with telbivudine therapy. Clin Ther 2013;35:1386-99
   PubMed Web of Science ®Google Scholar
• Lo AO, Wong VW, Wong GL, et al. Efficacy of entecavir switch therapy in chronic hepatitis B patients with incomplete virological response to telbivudine. Antivir Ther 2013;18(5):671-9
   PubMed Web of Science ®Google Scholar
• Pan CQ, Hu KQ, Yu AS, et al. Response to tenofovir monotherapy in chronic hepatitis B patients with suboptimal response to entecavir. J Viral Hepat 2012;19:213-19
   PubMed Web of Science ®Google Scholar
• Babusis D, Phan TK, Lee WA, et al. Mechanism for Effective Lymphoid Cell and Tissue Loading Following Oral Administration of Nucleotide Prodrug GS-7340. Mol Pharm 2013;10(2):459-66
   PubMed Web of Science ®Google Scholar
• Lai CL, Ahn SH, Lee KS, et al. Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Grimm D, Thimme R, Blum HE. HBV life cycle and novel drug targets. Hepatol Int 2011;5:644-53
   PubMed Web of Science ®Google Scholar
• Gripon P, Cannie I, Urban S. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol 2005;79(3):1613-22
   PubMed Web of Science ®Google Scholar
• Petersen J, Dandri M, Mier W, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008;26:335-41
   PubMed Web of Science ®Google Scholar
• Wu HL, Huang LR, Huang CC, et al. RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant. Gastroenterology 2005;128:708-16
   PubMed Web of Science ®Google Scholar
• Asif-Ullah M, Choi KJ, Choi KI, et al. Identification of compounds that inhibit the interaction between core and surface protein of hepatitis B virus. Antiviral Res 2006;70:85-90
   PubMed Web of Science ®Google Scholar
• Lv S, Wang J, Dou S, et al. Nanoparticles encapsulating hepatitis B virus cytosine-phosphate-guanosine induce therapeutic immunity against HBV infection. Hepatology 2014;59:385-94
   PubMed Web of Science ®Google Scholar
• Kitrinos KM, Corsa A, Liu Y, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology 2014;59(2):434-42
   PubMed Web of Science ®Google Scholar
• Study to evaluate the efficacy and safety of tenofovir disoproxil fumarate (TDF) in combination with peginterferon α-2a vs standard of care tenofovir disoproxil fumarate monotherapy or peginterferon α-2a monotherapy for 48 weeks in chronic hepatitis B(CHB). (TDF PEG CHB). Clinicaltrials.gov Identifier NCT01277601. Available from: http://clinicaltrials.gov/show/NCT01277601
   Google Scholar
• An open-label trial of 48-week peginterferon Alfa-2a (PEGASYS) to assess the sustained response of chronic hepatitis B patients with HBeAg seroconversion on nucleot(s)ide analogue therapy. Clinicaltrials.gov Identifier NCT02068365. Available from: http://clinicaltrials.gov/ct2/show/NCT02068365
   Google Scholar